Our Services
Medical Information
Helpful Resources
Published on: 8/18/2026
Suspected phosphate wasting is usually evaluated with fasting morning blood work (phosphate, calcium, creatinine, alkaline phosphatase, PTH, 25-hydroxy and 1,25-dihydroxy vitamin D) alongside paired urine testing to calculate fractional phosphate excretion or TmP/GFR, plus FGF23 when a renal leak is suspected. Depending on the pattern, clinicians may add tests for tubular dysfunction (urine glucose, amino acids, bicarbonate, pH), bone imaging, or genetic testing for inherited forms such as XLH. Test timing, recent supplement or medication use, and kidney function all change how results should be interpreted, so there are several important factors to consider before asking for a specific panel; see below to understand more.
Because low phosphate can stem from very different causes, from medication effects to inherited tubular disorders, knowing which pattern fits your symptoms helps you ask for the right tests instead of repeating the wrong ones. Take a free, instant online symptom check to clarify what may be driving your symptoms and to plan practical next steps with your clinician.
Last reviewed for medical accuracy: 08/18/2026
Phosphate is a mineral vital for strong bones, nerve function and energy production. Your kidneys help maintain the right phosphate balance by filtering out excess and returning what your body needs. When kidneys “leak” too much phosphate—a condition called phosphate wasting—blood levels drop, leading to fatigue, bone pain and, over time, weakened bones or fractures.
If you suspect phosphate wasting of kidney origin (“phosphate wasting kidney”), understanding which tests to request can help you and your doctor pinpoint the cause and guide treatment.
Early detection of phosphate wasting can:
Serum Phosphate
Serum Calcium and Magnesium
Comprehensive Metabolic Panel (CMP)
Parathyroid Hormone (PTH)
25-Hydroxy Vitamin D and 1,25-Dihydroxy Vitamin D
Fibroblast Growth Factor 23 (FGF23)
Alkaline Phosphatase (ALP)
24-Hour Urine Phosphate
Fractional Excretion of Phosphate (FEPO₄)
Tubular Maximum for Phosphate Reabsorption (TmP/GFR)
Urinalysis for Fanconi Syndrome Markers
Genetic Testing
Imaging Studies
Tumor-Induced Osteomalacia Panel
• Correlate blood tests with urine studies to confirm true renal phosphate loss.
• Elevated FGF23 or PTH levels guide hormonal causes.
• Genetic panels help in inherited conditions.
• Imaging pinpoints structural or tumor-related problems.
• Dietary Review
– Phosphate-poor diets worsen symptoms.
– Processed foods may contain hidden phosphates.
• Medication Check
– Some drugs (e.g., certain antibiotics, diuretics) can affect kidney phosphate handling.
• Symptom Tracking
– Note fatigue, muscle cramps, bone pain or dental issues.
– Consider a free, online symptom check, using the doctor approved Ubie Symptom Checker.
Remember to speak to a doctor about anything that could be life threatening or serious. Your healthcare team can tailor testing and therapy to your individual needs, ensuring you maintain strong bones, good energy and overall wellbeing.
(References)
* Schapira D, Ben Izhak O, Nachtigal A, Burstein A, Shalom RB, Shagrawi I, Best LA. Tumor-induced osteomalacia. Semin Arthritis Rheum. 1995 Aug;25(1):35-46. doi: 10.1016/s0049-0172(95)80016-6. PMID: 8525389.
* Santos F, Fuente R, Mejia N, Mantecon L, Gil-Peña H, Ordoñez FA. Hypophosphatemia and growth. Pediatr Nephrol. 2013 Apr;28(4):595-603. doi: 10.1007/s00467-012-2364-9. Epub 2012 Nov 22. PMID: 23179196.
* Ariyoshi N, Nogi M, Ando A, Watanabe H, Umekawa S. Hypophosphatemia-induced Cardiomyopathy. Am J Med Sci. 2016 Sep;352(3):317-23. doi: 10.1016/j.amjms.2016.04.013. Epub 2016 Apr 22. PMID: 27650239.
* Drivakos N, Hüsler C, Binet I. CME: Hypophosphatämie – was der Hausarzt wissen muss. Praxis (Bern 1994). 2017 Apr;106(8):399-403. doi: 10.1024/1661-8157/a002673. PMID: 28401778.
* Haffner D, Emma F, Eastwood DM, Biosse Duplan M, Bacchetta J, Schnabel D, Wicart P, Bockenhauer D, Santos F, Levtchenko E, Harvengt P, Kirchhoff M, Di Rocco F, Chaussain C, Brandi ML, Savendahl L, Briot K, Kamenicky P, Rejnmark L, Linglart A. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2019 Jul;15(7):435-455. doi: 10.1038/s41581-019-0152-5. PMID: 31068690; PMCID: PMC7136170.
* Florenzano P, Hartley IR, Jimenez M, Roszko K, Gafni RI, Collins MT. Tumor-Induced Osteomalacia. Calcif Tissue Int. 2021 Jan;108(1):128-142. doi: 10.1007/s00223-020-00691-6. Epub 2020 Jun 5. PMID: 32504138.
* Rush ET, Johnson B, Aradhya S, Beltran D, Bristow SL, Eisenbeis S, Guerra NE, Krolczyk S, Miller N, Morales A, Ramesan P, Sarafrazi S, Truty R, Dahir K. Molecular Diagnoses of X-Linked and Other Genetic Hypophosphatemias: Results From a Sponsored Genetic Testing Program. J Bone Miner Res. 2022 Feb;37(2):202-214. doi: 10.1002/jbmr.4454. Epub 2021 Nov 10. PMID: 34633109; PMCID: PMC9298723.
* Haffner D, Emma F, Seefried L, Högler W, Javaid KM, Bockenhauer D, Bacchetta J, Eastwood D, Biosse Duplan M, Schnabel D, Wicart P, Ariceta G, Levtchenko E, Harvengt P, Kirchhoff M, Gardiner O, Di Rocco F, Chaussain C, Brandi ML, Savendahl L, Briot K, Kamenický P, Rejnmark L, Linglart A. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2025 May;21(5):330-354. doi: 10.1038/s41581-024-00926-x. Epub 2025 Jan 15. PMID: 39814982.
* Khan AA, Ali DS, Appelman-Dijkstra NM, Carpenter TO, Chaussain C, Imel EA, Jan de Beur SM, Florenzano P, Abu Alrob H, Aldabagh R, Alexander RT, Alsarraf F, Beck-Nielsen SS, Biosse-Duplan M, Cohen-Solal M, Crowley RK, Dandurand K, Filler G, Friedlander L, Fukumoto S, Gagnon C, Goodyer P, Grasemann C, Grimbly C, Hussein S, Javaid MK, Khan S, Khan A, Lehman A, Lems WF, Lewiecki EM, McDonnell C, Mirza RD, Morgante E, Morrison A, Portale AA, Rhee Y, Rush ET, Siggelkow H, Tetradis S, Tosi L, Ward LM, Guyatt G, Brandi ML. X-Linked Hypophosphatemia Management in Adults: An International Working Group Clinical Practice Guideline. J Clin Endocrinol Metab. 2025 Jul 15;110(8):2353-2370. doi: 10.1210/clinem/dgaf170. PMID: 40243526; PMCID: PMC12261105.
* Böckmann I, Haffner D. The Diagnosis and Therapy of XLH. Calcif Tissue Int. 2025 Apr 28;116(1):66. doi: 10.1007/s00223-025-01374-w. Epub 2025 Apr 28. PMID: 40295317; PMCID: PMC12037658.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.